Expanding Patent Protection in Singapore
Genprex, a clinical-stage company pioneering gene therapy solutions, recently scored a victory in Singapore with the grant of a patent for the utilization of Reqorsa® Gene Therapy alongside PD-1 antibodies, extending protection rights until 2037.
Global Coverage for Pioneer Drug Combinations
This new patent reinforces Genprex’s existing protections in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea, indicating a significant step forward in shielding its pioneering drug combinations utilizing REQORSA and PD-1 antibodies.
Advancements in Lung Cancer Therapy
In a watershed moment for cancer treatment, Genprex’s innovative Acclaim-3 study combines REQORSA with Genentech’s Tecentriq®, showcasing considerable promise as a maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC).
Revolutionizing Cancer Treatment
PD-1 inhibitors and PD-L1 inhibitors represent cutting-edge immunotherapies that target cancer cells and halt the activity of PD-1 and PDL1 checkpoint proteins, showcasing a groundbreaking approach to combating cancer.
Paving the Way for Future Breakthroughs
Genprex’s Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, Esq., expressed enthusiasm for the new patent’s significance in fortifying the company’s position and expanding its reach in Asian markets, particularly in the battle against lung cancer.
Impact of the Asian Market
With Asia accounting for over 63% of new lung cancer cases globally in 2022, the region represents a critical battleground in the fight against cancer, underscoring the importance of Genprex’s strategic patent victories.
About Genprex, Inc.
Genprex, Inc. is a visionary gene therapy company focused on revolutionizing cancer and diabetes treatment. Leveraging cutting-edge technologies, Genprex develops innovative therapies that target large patient populations, ushering in a new era of disease management.